Back

Potential hematopoietic effects of SGLT2 inhibitors in patients with cardiac amyloidosis.

30 August 2024 (12:00 - 12:40)
Organised by: Logo
Congress Presentation Part of: Primary care for the elderly patient: practical aspects Cardiovascular Disease in the Elderly ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Nikita Ermolaev

Medical University of Vienna, Vienna (Austria)

6 More presentations in this session

Presentation thumbnail
Systemic inflammation in patients with atherosclerotic cardiovascular and chronic kidney disease in Spain: a population-based study using electronic medical records from a primary care database.
Doctor G. Pesce (Milano, IT)
Abstract Slides Video
Presentation thumbnail
Active surveillance for cardiac complications after major noncardiac surgery: implications on resource utilization and safety in high-risk patients
Ms M. Pargger (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Different impact of chronic kidney disease in older patients with heart failure according to frailty
Doctor A. Esteban Fernandez (Leganes, ES) Mr C. Jimenez Mendez (Cadiz, ES)
Abstract Slides Video
Presentation thumbnail
Controlling Nutritional Status (CONUT) Score: a new tool for characterization and prognosis of patients with infective endocarditis
Doctor C. Perez Garcia (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Long-term mortality outcomes of southeast asian patients with aortic stenosis
Doctor K. Ching (Singapore, SG)
Abstract Slides Video

Access the full session

Session thumbnail
Primary care for the elderly patient: practical aspects

The Event

Event poster

ESC Congress 2024

30 August 2024 12:00 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2 inhibitor treatment in patients with cardiac amyloidosis
thumbnail
Congress Presentation
Effects of SGLT-2 inhibitors on erythropoiesis and the associated cardio-renal benefits in patients with chronic heart failure
thumbnail
Congress Presentation
Hemoglobin, hematocrit and heart failure: the SGLT2 inhibitor connection

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources